A5011966705- CAR-T cell therapy research
- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- Phagocytosis and Immune Regulation
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- RNA Interference and Gene Delivery
- Chronic Lymphocytic Leukemia Research
- Virus-based gene therapy research
- CRISPR and Genetic Engineering
- Biosimilars and Bioanalytical Methods
- Extracellular vesicles in disease
- Hematopoietic Stem Cell Transplantation
- Neuroblastoma Research and Treatments
- Cancer Research and Treatments
- Silicon Carbide Semiconductor Technologies
- HER2/EGFR in Cancer Research
- Viral-associated cancers and disorders
- Asthma and respiratory diseases
- Acute Lymphoblastic Leukemia research
- Nanowire Synthesis and Applications
- Adenosine and Purinergic Signaling
- Pluripotent Stem Cells Research
Carisma Therapeutics (United States)
2020-2025
University of Pennsylvania
2015-2023
Translational Therapeutics (United States)
2017
California University of Pennsylvania
2016
The Wistar Institute
2011-2012
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses emerged a major problem that is observed in approximately 30% treated patients. Developing approaches to preventing treating antigen-loss escapes would therefore represent vertical advance field. Here, we found primary patient samples, IL-3...
Patients with otherwise treatment-resistant Hodgkin lymphoma could benefit from chimeric antigen receptor T-cell (CART) therapy. However, lacks CD19 and contains a highly immunosuppressive tumor microenvironment (TME). We hypothesized that in lymphoma, CART should target both malignant cells the TME. demonstrated CD123 on TME, including tumor-associated macrophages (TAM). In vitro, convert toward TAMs inhibit proliferation. contrast, anti-CD123 recognized killed TAMs, thus overcoming...
Responses to therapy with chimeric antigen receptor T cells recognizing CD19 (CART19, CTL019) may vary by histology. Mantle cell lymphoma (MCL) represents a B-cell malignancy that remains incurable despite novel therapies such as the BTK inhibitor ibrutinib, and where data from CTL019 are scant. Using MCL model, we sought build upon outcomes ibrutinib combining these in rational manner.
Epstein-Barr Virus (EBV) can establish latent infections with distinct gene expression patterns referred to as latency types. These different types are epigenetically stable and correspond promoter utilization. Here we explore the three-dimensional conformations of EBV genome in We employed Chromosome Conformation Capture (3C) assay investigate chromatin loop formation between OriP enhancer promoters that determine type I (Qp) or III (Cp) expression. show is close physical proximity Qp...
Asthma, a common disorder that affects >250 million people worldwide, is defined by exaggerated bronchoconstriction to inflammatory mediators including acetylcholine (ACh), bradykinin and histamine—also termed airway hyper-responsiveness. Nearly 10% of with asthma have severe, treatment-resistant disease, which frequently associated immunoglobulin-E sensitization ubiquitous fungi, typically Aspergillus fumigatus (Af). Here we show major Af allergen, Asp f13, serine protease, alkaline...
2533 Background: Most solid tumors are resistant to immunotherapy. In pre-clinical studies, CAR-M infiltrate tumors, phagocytose tumor cells, activate the micro environment (TME), recruit T and present antigens cells leading robust anti-tumor immunity. CT-0508 is a first in class CAR-M, comprised of autologous monocyte derived macrophages expressing an anti-HER2 CAR. Here we preliminary clinical results from Phase 1 FIH study. Methods: This multi-center, open-label study evaluating CT-0508’s...
Abstract Despite the remarkable efficacy achieved by CAR-T cell therapy in hematologic malignancies, translating these results solid tumors remains challenging. We previously developed human CAR-M and demonstrated that adoptive transfer of into xenograft models cancer controls tumor progression improves overall survival1. Herein, we established a fully immunocompetent syngeneic mouse model evaluated interaction with microenvironment (TME) endogenous adaptive immune system. Murine bone...
TPS2666 Background: Macrophages are abundant in the solid tumor microenvironment (sTME) and can promote growth (M2) or enhance anti-tumor immunity (M1). CAR expression redirect macrophage function to selectively target phagocytose antigen overexpressing cancer cells. CAR-M reprogram sTME present neoantigens T cells, leading epitope spreading immunity. CT-0508 is comprised of autologous monocyte-derived proinflammatory macrophages expressing an anti-HER2 CAR. Pre-clinical studies showed that...
TPS2682 Background: Myeloid cells are actively recruited to the solid tumor microenvironment (TME) and have potential mediate control via phagocytosis, TME remodeling, T cell activation. We previously developed human chimeric antigen receptor macrophages (CAR-M) shown potent anti-tumor activity in pre-clinical models. The anti-HER2 CAR-M therapy product, CT-0508, is currently being evaluated a Phase I trial as monotherapy combination with pembrolizumab. Early clinical data feasibility,...
Chimeric antigen receptor T (CART) cell therapy results in impressively high remission rates B neoplasms but is limited by the development of cytokine release syndrome (CRS). While use anti-IL6 antibody tocilizumab with or without steroids can reverse this syndrome, there concern that early immunosuppression could impair anti-tumor activity and therefore reserved for severe CRS. Ruxolitinib a JAK/STAT pathway inhibitor has resulted significant reduction inflammatory cytokines preclinical...